DBS flags Innovent cash and investment fair value impact
DBS Group Research says Innovent Biologics’ enlarged cash holdings and investment fair-value gains could bolster earnings over 2026-2028.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.